Declare the records
The pilot starts with the same ten selected ClinicalTrials.gov records shown in this sample: two records for each of five named assets.
Proposed pilot · Research operations
Keep a fixed trial portfolio in view.
For research and competitive-intelligence teams that repeatedly compare the same registry records, the proposed PeptideScanner monitor turns those checks into a concise, source-linked report with an export your team can reuse.
The public sample below is a dated baseline format check. Recurring delivery remains a proposal until cadence and delivery are separately reviewed.
A narrow workflow
Make recurring comparison easier to review.
The proposed pilot keeps attention on a declared set of records and the fields that change the shape of a recurring report. Each check can show a changed field, a no-change result, a first observation, or a source-check failure, with the original registry record attached.
That gives a team a compact handoff: what the source currently says, what changed since the last successful observation, and where the source window has a gap.
The proposed workflow
A fixed scope keeps the question answerable.
Compare tracked fields
Status, phase, enrollment, completion dates, sponsor, and source-posted update date stay in a stable machine-readable shape.
Review before delivery
A digest would be reviewed before delivery. The monitor reports source metadata without interpreting clinical meaning.
Founding pilot proposal
One clear report for the records your team keeps checking.
The proposed first service period is designed for one organization and one designated business recipient. It covers this fixed ClinicalTrials.gov scope, source-linked before/after observations after the recurring workflow is verified, explicit no-change checks, and source gaps when a check cannot be completed.
The pilot excludes new-trial discovery, literature and regulator monitoring, medical or legal interpretation, dosing or purchasing guidance, and bespoke research.
Dated public sample
The first check is a baseline, not a change report.
On Sep 5, 2026, all 10 selected records produced first observations. The sample shows 10 baseline results, with 0 changes and 0 failed checks represented. There is no prior observation in this dated sample, so it makes no claim about a change or an established seven-day cadence.
Each card links to the exact ClinicalTrials.gov record supporting the displayed registry fields. The public downloads contain the same source-linked baseline and tracked fields.
10records checked
5named assets
10baseline results
0changes shown
- Registry status
- Active Not Recruiting
- Phase
- Phase 1
- Enrollment
- 96 (estimated)
- Source update posted
- Aug 13, 2026 (actual)
- Lead sponsor
- Novo Nordisk A/S
- Completion
- Primary Sep 12, 2026 (estimated) · Overall Sep 25, 2026 (estimated)
- Registry status
- Recruiting
- Phase
- Phase 3
- Enrollment
- 622 (estimated)
- Source update posted
- Aug 12, 2026 (actual)
- Lead sponsor
- VA Office of Research and Development
- Completion
- Primary Mar 31, 2029 (estimated) · Overall Mar 30, 2030 (estimated)
- Registry status
- Recruiting
- Phase
- Phase 2
- Enrollment
- 120 (estimated)
- Source update posted
- Aug 12, 2026 (actual)
- Lead sponsor
- National Institute on Alcohol Abuse and Alcoholism (NIAAA)
- Completion
- Primary Jul 30, 2027 (estimated) · Overall Jul 30, 2027 (estimated)
- Registry status
- Recruiting
- Phase
- Phase 1 · Phase 2
- Enrollment
- 156 (estimated)
- Source update posted
- Aug 12, 2026 (actual)
- Lead sponsor
- Alnylam Pharmaceuticals
- Completion
- Primary Apr 27, 2027 (estimated) · Overall Mar 2, 2028 (estimated)
- Registry status
- Completed
- Phase
- Phase 3
- Enrollment
- 1,946 (actual)
- Source update posted
- Jul 30, 2026 (actual)
- Lead sponsor
- Eli Lilly and Company
- Completion
- Primary Apr 16, 2026 (actual) · Overall May 14, 2026 (actual)
- Registry status
- Completed
- Phase
- Phase 3
- Enrollment
- 1,152 (actual)
- Source update posted
- Jul 30, 2026 (actual)
- Lead sponsor
- Eli Lilly and Company
- Completion
- Primary Jun 16, 2026 (actual) · Overall Jun 16, 2026 (actual)
- Registry status
- Recruiting
- Phase
- Phase 3
- Enrollment
- 285 (estimated)
- Source update posted
- Sep 4, 2026 (actual)
- Lead sponsor
- Novo Nordisk A/S
- Completion
- Primary May 18, 2027 (estimated) · Overall Jul 6, 2027 (estimated)
- Registry status
- Active Not Recruiting
- Phase
- Phase 3
- Enrollment
- 330 (estimated)
- Source update posted
- Sep 4, 2026 (actual)
- Lead sponsor
- Novo Nordisk A/S
- Completion
- Primary May 12, 2027 (estimated) · Overall Jun 30, 2027 (estimated)
- Registry status
- Completed
- Phase
- Phase 3
- Enrollment
- 5,531 (actual)
- Source update posted
- Sep 3, 2026 (actual)
- Lead sponsor
- Boehringer Ingelheim
- Completion
- Primary Jun 1, 2026 (actual) · Overall Jun 30, 2026 (actual)
- Registry status
- Recruiting
- Phase
- Phase 3
- Enrollment
- 1,800 (estimated)
- Source update posted
- Aug 21, 2026 (actual)
- Lead sponsor
- Boehringer Ingelheim
- Completion
- Primary Dec 27, 2031 (estimated) · Overall Dec 27, 2031 (estimated)
Machine-readable sample
Use the same public projection in a report or a script.
The JSON and CSV endpoints contain the exact dated baseline shown above: the declared scope, result counts, tracked fields, checked date, and direct source URLs.
JSONDownload JSON ↓
Structured record set
Scope and ten baseline records in one stable object.
{
"schemaVersion": "portfolio-monitor-public-sample/v1",
"checkedDate": "2026-09-05",
"records": [
{
"asset": "semaglutide",
"recordId": "NCT07087795",
"outcome": "baseline",
"checkedDate": "2026-09-05",
"sourceUrl": "https://clinicaltrials.gov/study/NCT07087795",
"fields": {
"status": "ACTIVE_NOT_RECRUITING",
"phase": [
"PHASE1"
],
"enrollmentCount": 96,
"enrollmentType": "ESTIMATED",
"completionDates": {
"primary": {
"date": "2026-09-12",
"type": "ESTIMATED"
},
"overall": {
"date": "2026-09-25",
"type": "ESTIMATED"
}
},
"sponsor": {
"name": "Novo Nordisk A/S",
"class": "INDUSTRY"
},
"lastUpdatePostDate": {
"date": "2026-08-13",
"type": "ACTUAL"
}
}
}
]
}Spreadsheet-ready rows
One row per record, with tracked fields and a source link.
"sample_date","asset","record_id","outcome","checked_date","source_last_updated","source_last_updated_type","status","phase","enrollment_count","enrollment_type","completion_primary_date","completion_primary_type","completion_overall_date","completion_overall_type","sponsor_name","sponsor_class","source_url"
"2026-09-05","semaglutide","NCT07087795","baseline","2026-09-05","2026-08-13","ACTUAL","ACTIVE_NOT_RECRUITING","PHASE1","96","ESTIMATED","2026-09-12","ESTIMATED","2026-09-25","ESTIMATED","Novo Nordisk A/S","INDUSTRY","https://clinicaltrials.gov/study/NCT07087795"Read the boundary
Useful because the limits stay visible.
- Selected coverage. Two selected records per named asset are a transparent sample, not a complete portfolio and not new-trial discovery.
- Registry metadata. A status, sponsor, enrollment, phase, or date in ClinicalTrials.gov describes that registry record. It does not establish efficacy, safety, treatment value, or clinical significance.
- Recurring workflow first. This baseline does not prove a seven-day cadence, a weekly delivery, or a paid service. Those require separate review.
Contact PeptideScanner
Questions, corrections, or a recurring research task?
Send a note to hello@peptidescanner.com with your question, a page and source to check, or the repeated report task you want to make easier. Pilot inquiries start with the fixed public scope shown here.